Clovis (rated at Outperform, $100 target price) is currently not an earnings-driven story. The spotlight remains on CO-1686 as a treatment for first-line epidermal growth factor receptor mutations (EGFRm+) and second-line EGFRm-T790M+ non-small cell lung cancer (NSCLC). Patient identifiable (PI) data presented at the American Society of Clinical Oncology (ASCO) meeting showed that CO-1686 and [AstraZeneca's (AZN)] AZD9291's efficacy was highly comparable. Safety was the key focus with the street positioning AZD9291 having a cleaner safety profile than CO-1686. The call may provide management to expand the insulin-like growth factor 1 receptor (IGF1R) hypothesis. We anticipate additional attention on: 1) updates on Lucitinib phase II trials in advanced breast cancer (FGFR1-amp, 11q-amp, FGF-WT) and squamous NSCLC (FGFR1-amp); 2) updates on ARIEL2 phase II biomarker trial and ARIEL3 phase III trial both for Rucaparib in platinum-sensitive, relapsed ovarian cancer.
Wow...I'm assuming you were delirious when you composed the above post this morning. Stock is being battered and actually fell from $90+ to $40 in less than 60 days BEFORE Yellen spoke.
"this will move higher today".....guess Ms Yellen isn't the only one who doesn't know"biotech etc. or stocks". cheers
most amazing nonsense i have seen in a long time….what the flick does that dix brain know about biotech etc.or stocks for that matter.SHUT YOUR MOUTH U DUMB KLUNT,AND DO YOUR JOB,WHICH IS NOT BEING A STOCK GURU.
Honey, go back to bed, 5-year old kids should not be posting on the Yahoo! boards about Daddy's company
Sorry but the jury is out on whether the drugs are 'excellent'. The primary trial results were less than stellar a few weeks ago.....hence the dramatic stock decline. However if future trial results end up to be 'excellent' then the stock will soar. If there are more disappointments in store....Katie bar the door. cheers
Guess we'll state the obvious. Wall Street was terribly disappointed with the trial results released a few weeks ago. Until there is better news stock will stay range bound. This is in spite of what the posters are saying about buyouts, $58 in short order, $68 soon, and $100 whenever. Highly speculative stock that totally depends on trial results. Not for the faint of heart. cheers
Was a great two weeks for many biotech companies. Many recouped all the losses they experienced in early June. Some have reached new highs by erasing substantial losses. Of course, all did not participate. cheers
Amazing - and CLVS already has FDA Fast Track Approval. Such manipulation.